Fed Chair Powell's dovish Jackson Hole speech sparks a market rally, while tech dips and earnings drive individual stocks ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Rocket can resume gene therapy trial after FDA lifts hold The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...

Hims & Hers Health Inc. HIMS shares are trading lower Tuesday after GoodRx Inc. GDRX announced a collaboration with Novo ...

GoodRx reports that insurance formularies are shrinking, leading to fewer covered medications and increased restrictions on ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

After Novo Nordisk revealed Ozempic will retail for half-price at 70,000 pharmacies throughout the US, people are questioning ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.